Purpose: To describe a case of choroidal malignant melanoma in a child without ocular melanocytosis.
Methods: A 6-year-old girl presented with misalignment of the right eye of a few weeks' duration. Visual acuity was counting fingers in the right eye and 20/20 in the left eye. Ophthalmoscopy of the right eye revealed a well defined choroidal mass in the macular region measuring 10 mm in diameter with overlying subretinal fluid. Ultrasonography revealed that the mass was 10.1 mm thick with choroidal excavation. On the basis of clinical and ultrasonographic findings, the diagnosis was choroidal melanoma without ocular melanocytosis. The eye was enucleated.
Results: Histopathologic examination revealed malignant melanoma of the choroid. There was not extrascleral extension.
Conclusion: Choroidal malignant melanoma can occur in young patients, even in the absence of melanocytosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/ICB.0b013e31816bbefb | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A prospective, multicenter analysis of the integrated 31-gene expression profile test for sentinel lymph node biopsy (i31-GEP for SLNB) test demonstrates reduced number of unnecessary SLNBs in patients with cutaneous melanoma.
World J Surg Oncol
January 2025
Summit Medical Group, Bend, OR, USA.
Background: National Comprehensive Cancer Network guidelines recommend sentinel lymph node biopsy (SLNB) for patients with > 10% risk of positivity, consider SLNB with 5-10% risk, and foregoing with < 5% risk. The integrated 31-gene expression profile (i31-GEP) algorithm combines the 31-GEP with clinicopathologic variables, estimating SLN positivity risk.
Methods: The i31-GEP SLNB risk prediction accuracy was assessed in patients with T1-T2 tumors enrolled in the prospective, multicenter DECIDE study (n = 322).
Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial.
Nat Med
January 2025
BioNTech US, Cambridge, MA, USA.
New treatment approaches are warranted for patients with advanced melanoma refractory to immune checkpoint blockade (ICB) or BRAF-targeted therapy. We designed BNT221, a personalized, neoantigen-specific autologous T cell product derived from peripheral blood, and tested this in a 3 + 3 dose-finding study with two dose levels (DLs) in patients with locally advanced or metastatic melanoma, disease progression after ICB, measurable disease (Response Evaluation Criteria in Solid Tumors version 1.1) and, where appropriate, BRAF-targeted therapy.
View Article and Find Full Text PDFEfficacy of PDD-guided tumor excision combined with photodynamic therapy in cutaneous squamous cell carcinoma.
Photodiagnosis Photodyn Ther
January 2025
Department of Plastic & Cosmetic Surgery, Daping Hospital, Army Medical University, Chongqing 400042, China. Electronic address:
Background: Cutaneous squamous cell carcinoma (cSCC) is an aggressive tumor with unclear margins. Photodynamic diagnosis (PDD) enables the differentiation of tumor tissue from normal tissue via visible fluorescence. Photodynamic therapy (PDT) is widely used in the treatment of non-melanoma skin tumors.
View Article and Find Full Text PDFLong afterglow hybrid nanoplatform for integrated NIR-Ⅱ imaging diagnosis and triple-synergistic treatment of choroidal melanoma.
Talanta
December 2024
The Key Laboratory of Nonferrous Metal Chemistry and Resources Utilization of Gansu Province and State Key Laboratory of Applied Organic Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, 730000, PR China. Electronic address:
The key to the treatment of choroidal melanoma (CM) is to improve diagnostic efficiency and find a high-performance treatment to replace the traditional treatment of radiotherapy and enucleation. In this paper, for the first time, long afterglow luminescence material was applied to the integrated diagnosis and treatment of eyes, with its unique advantages in photoluminescence and afterglow luminescence to solve the bottleneck problem of real-time irradiation required for photothermal and photodynamic therapy (PTT and PDT). Based on the excellent photoluminescence and afterglow properties of ZnGaGeO:CrYbEr (ZGGO) nanoparticles, a nanoplatform ZGGO@Au@UiO-66@ZnPc:Dox-FA (GAUZD-FA) for NIR-Ⅱ imaging and triple-synergistic therapy (PTT, PDT and sustained-release drug) was constructed.
View Article and Find Full Text PDFAromatic compounds and organic acids identified from Ganoderma formosanum exhibit synergistic anti-melanogenic effects.
J Food Drug Anal
December 2024
Institute of Food Science Technology, National Taiwan University, No. 1, Sec. 4, Roosevelt Rd., Taipei, Taiwan, R.O.C.
This study reveals the anti-tyrosinase activity of Ganoderma formosanum extracts, pinpointing compounds including gluconic acid, mesalamine, L-pyroglutamic acid, esculetin, 5-hydroxyindole, and salicylic acid, as effective melanin production inhibitors in melanoma cells and zebrafish embryos. Furthermore, multiple molecular docking simulations provided insights into interactions between the identified compounds and tyrosinase, increasing binding affinity up to -16.36 kcal/mol.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!